The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $14.39

Today's change+0.05 +0.35%
Updated August 18 4:01 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $14.39

Today's change+0.05 +0.35%
Updated August 18 4:01 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up (U.S.)$0.05

Valeant Pharmaceuticals International Inc closed up Friday by (U.S.)$0.05 or 0.35% to (U.S.)$14.39. Over the last five days, shares have gained 3.60%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 61.61% during the last year.

Key company metrics

  • Open(U.S.) $14.36
  • Previous close(U.S.) $14.34
  • High(U.S.) $14.54
  • Low(U.S.) $14.17
  • Bid / Ask-- / --
  • YTD % change-0.90%
  • Volume10,472,002
  • Average volume (10-day)20,168,517
  • Average volume (1-month)15,422,362
  • Average volume (3-month)20,985,177
  • 52-week range(U.S.) $8.31 to (U.S.) $32.75
  • Beta-0.36
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward3.88×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.27
Updated August 18 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-12.35%

Valeant Pharmaceuticals International Inc has a net profit margin of -12.35%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.54%Sector:Industry:

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue2,2332,1092,4032,480
Total other revenue--------
Total revenue2,2332,1092,4032,480
Gross profit1,5871,5131,7371,822
Total cost of revenue646596665658
Total operating expense2,0581,9622,2523,343
Selling / general / administrative659661665661
Research & development949693101
Depreciation / amortization623635284807
Interest expense (income), net operating--------
Unusual expense (income)38-274531,115
Other operating expenses, total-21931
Operating income175147150-863
Interest income (expense), net non-operating-459-474-467-470
Gain (loss) on sale of assets--------
Other--------
Income before tax-242-295-360-1,332
Income after tax-37629-512-1,219
Income tax, total-205-924152-113
Net income-38628-515-1,218
Total adjustments to net income--------
Net income before extra. items-38628-515-1,218
Minority interest-1-1-31
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-38628-515-1,218
Inc. avail. to common incl. extra. items-38628-515-1,218
Diluted net income-38628-515-1,218
Dilution adjustment--------
Diluted weighted average shares350351350350
Diluted EPS excluding extraordinary itemsvalue per share-0.111.79-1.47-3.49
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.041.77-0.65-1.38